Table 3. Adverse events in HSCT group of all included studies.

Study	N. affected/N. evaluated patients	Specification
Treatment-related mortality
Bisogno 2009 [39]	3/70	2x sepsis, 1x capillary leak syndrome
Carli 1999* [36], [107]	1/52	Sepsis
Chan 1991 [44]	1/1	Renal failure, acute respiratory distress syndrome, and aluminium cardiomyopathy
Ekert 1984 [45]	1/2	Sepsis
Hara 1998 [51]	1/3	Renal tubular acidosis
Hawkins 2002 [52]	1/6	Acute respiratory distress syndrome
Kwon 2010 [59]	1/3	Sepsis with multiorgan failure and major bleeding
Sanz 1997 [72]	1/1	Acute renal failure
Secondary neoplasia
Yamada 2007 [40]	1/7	Myelodysplastic syndrome
Non-hematological toxicity
Carli 1999 [36], [107]	0/30	Liver toxicity
Hara 1998 [51]	2/7	Kidney toxicity
Lucidarme 1998 [62]	0/5	Liver as well as kidney toxicity
Williams 2004 [75]	0/4	Liver as well as kidney toxicity
Williams 2004 [75]	1/4	Heart toxicity

*Carli 1999: in addition, 1 TRM was reported for the control group (anthracycline-related cardiotoxicity); in the follow-up paper Carli 2004, a total of 6 TRM were reported. However, the assignment to the treatment groups was not clear.

^†National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grade III to IV.

Abbreviation. HSCT: hematopoietic stem cell transplantation.